New Immunotherapy Supplier for High-Risk Neuroblastoma - Child Cancer Network
17612
post-template-default,single,single-post,postid-17612,single-format-standard,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

New Immunotherapy Supplier for High-Risk Neuroblastoma

New Immunotherapy Supplier for High-Risk Neuroblastoma

A New European supplier of Dinutximab Beta has been confirmed, ensuring the ongoing provision of fully-funded, standard of care immunotherapy for high-risk neuroblastoma.

Click here for a full update.

No Comments

Post A Comment